Comparison of insulin aspart vs. regular human insulin with or without insulin detemir concerning adipozytokines and metabolic effects in patients with type 2 diabetes mellitus

Experimental and Clinical Endocrinology and Diabetes

Volumn 121, Issue 4, 2013, Pages 210-213

  Herrmann, B L ^a,b   Kasser, C ^a   Keuthage, W ^c   Huptas, M ^d   Dette, H ^e   Klute, A ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Division of Laboratory Research   (Germany)

^c Division of Diabetetology   (Germany)

^d Division of Diabetology   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

adipocytokines; insulin; type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; NEUTRAL INSULIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADIPONECTIN; ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN ASPART; INSULIN, LONG-ACTING; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84876496874     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0033-1334905     Document Type: Article

References (24)

1. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes May: 1999; 48 937 942 (Pubitemid 29226337)
2. Eckel R. H., Alberti K. G., Grundy S. M. et al. The metabolic syndrome. Lancet Jan 16: 2010; 375 181 183
3. Cavalot F., Pagliarino A., Valle M. et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care Oct: 2011; 34 2237 2243
4. Nathan D. M., Buse J. B., Davidson M. B. et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia: 2006; 49 1711 1721 (Pubitemid 44025023)
5. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia: 2003; 46 01 M9 M16 (Pubitemid 36543098)
6. Blaak E. E., Antoine J. M., Benton D. et al. Impact of postprandial glycaemia on health and prevention of disease. Obes Rev: 2012
7. Siebenhofer A., Plank J., Berghold A. et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev: 2006; CD003287
8. Hermansen K., Fontaine P., Kukolja K. K. et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia: 2004; 47 622 629 (Pubitemid 38658363)
9. Menzaghi C., Trischitta V., Doria A. Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes: 2007; 56 1198 1209 (Pubitemid 46715598)
10. Herrmann B. L., Saller B., Stratmann M. et al. Effects of a combination of rhGH and metformin on adiponectin levels in patients with metabolic syndrome. Horm Metab Res: 2005; 37 49 52 (Pubitemid 40269453)
11. Turer A. T., Scherer P. E. Adiponectin: mechanistic insights and clinical implications. Diabetologia: 2012
12. Schernthaner G., Barnett A. H., Betteridge D. J. et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia: 2010; 53 1258 1269
13. Gram J., Henriksen J. E., Grodum E. et al. Pharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes Study. Diabetes Care: 2011; 34 27 33
14. Siegmund T., Weber S., Blankenfeld H. et al. Comparison of insulin glargine versus NPH insulin in people with Type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin. Exp Clin Endocrinol Diabetes: 2007; 115 349 353 (Pubitemid 46999715)
15. Bretzel R. G., Nuber U., Landgraf W. et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet: 2008; 371 1073 1084 (Pubitemid 351436611)
16. Holman R. R., Farmer A. J., Davies M. J. et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med: 2009; 361 1736 1747
17. Gross J. L., Kramer C. K., Leitao C. B. et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med: 2011; 154 672 679
18. Crandall J. P., Shamoon H., Cohen H. W. et al. Post-challenge hyperglycemia in older adults is associated with increased cardiovascular risk profile. J Clin Endocrinol Metab: 2009; 94 1595 1601
19. Silbernagel G., Sourij H., Grammer T. B. et al. Isolated post-challenge hyperglycaemia predicts increased cardiovascular mortality. Atherosclerosis: 2012
20. Zhu N., Pankow J. S., Ballantyne C. M. et al. High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC study. J Clin Endocrinol Metab: 2010; 95 5097 5104
21. Pischon T., Girman C. J., Hotamisligil G. S. et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA: 2004; 291 1730 1737 (Pubitemid 38489895)
22. Cavusoglu E., Ruwende C., Chopra V. et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J: 2006; 27 2300 2309 (Pubitemid 44453573)
23. Dluhy R. G., McMahon G. T. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med: 2008; 358 2630 2633 (Pubitemid 351831365)
24. Seaquist E. R., Miller M. E., Bonds D. E. et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care: 2012; 35 409 414